UTHR|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $6.96 | - | - |
| Q2'26 | $6.97 | $7.27 | +4.3% |
| Q4'25 | $7.33 | $7.70 | +5.1% |
| Q4'24 | $6.27 | $6.19 | -1.2% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $807M | - | - |
| Q2'26 | $822M | $783M | -4.7% |
| Q4'25 | $829M | $790M | -4.7% |
| Q4'24 | - | $736M | - |
UTHR|Monthly Returns
Market Data
UTHR Stock Snapshot
- Market cap
- 21.22B
- P/E ratio
- 16.2
- Day range
- $491.25 – $497.70
- News sentiment
- 58/100 · Neutral
- Analyst target
- $664.33 (+34.6%)
- Consensus
- Buy · 24 analysts
UTHR is on the weaker side of its setup, with little confirmation for a reversal yet. Earnings and guidance carry more weight than macro data at this capitalisation.
Behaviour On Record
What UTHR's own history says about today's numbers
- Realized volatility (21d)
- 22.9% 21st pct
- Below its peak
- -16.2%
- vs 200-day average
- -5.2%
- Up days (1y)
- 47%
United Therapeutics Corporation is currently running 22.9% annualised volatility over the last 21 sessions. Measured against UTHR's own 13 years of daily returns rather than a market-wide average, that is the 21st percentile — unusually subdued by its own history, against a typical reading of 29.9%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.
UTHR is trading -16.2% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -29.5%, and the deepest was -41.1% in 2019. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.
Price sits -5.2% from its 200-day moving average. Against every other day in its history, that gap ranks at the 27th percentile — a narrower gap than it typically runs. Over the past year UTHR closed higher on 47% of sessions, and it is currently 1 session into a rising streak.
On September specifically: over 13 years of records, UTHR finished the month higher 4 of 13 times, with a median return of -3.1% and an average of -2.5%. Its strongest month historically has been October at +5.8% on average, its weakest September at -2.5%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.
Overnight risk is measurable too: UTHR has opened more than 2% away from the prior close in 124 of 3,267 sessions (3.8% of the time), with the largest gaps running +51.0% and -12.9%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.
All figures computed from 3,268 daily closes between 2013-09-23 and 2026-09-21, split-adjusted, recomputed daily. Percentiles are against UTHR's own 13-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of UTHR's sector?
United Therapeutics Corporation sits in the Health Care sector, currently ranked 5th of 11 GICS sectors by relative-strength rotation score (improving).
- Sector rank
- #5 of 11
- Sector state
- Improving
- Sector rotation score
- 80
Analyst Rating Changes
Are analysts turning bullish or bearish on UTHR?
RBC Capital most recently reiterated its rating on United Therapeutics Corporation to Outperform on Aug 6, 2026 with a price target of $677 (from $704). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.
- Latest action
- RBC Capital — Outperform
- 90-day upgrades
- 0
- 90-day downgrades
- 0
- Net rating momentum
- 0
UTHR Competitive Positioning
- UTHRyou're hereUnited Therapeutics Corporation$21.2B-0.20%
- ZTSZoetis Inc.$29.5B+0.42%
- VTRSViatris Inc.$19.5B+1.65%